Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2014 amounted to $20.3 billion, and approximately 5 billion in Q1 2015. For more information, visit www.tevapharm.com.

Operating Income(1) and Cash Flow

Net Revenues

Earnings Per Share (non GAAP) (1)

Stock Chart

Dividends Per Share

(1) See non GAAP reconciliation in our report for the (first quarter of 2015).
Q1 2015 Business Highlights

**Generics:**
- Revenue 2.6 billion, up 9% over Q1 2014
- Profit** up 950 bps over Q1 2014
- Successful Launch of Generic Nexium
- International Growth Markets – Double digit growth in local currency terms
- EU – Strong performance in Germany, UK and Italy. Record profitability levels
- OTC revenues up 20% in local currency terms

**Specialty:**
- Copaxone 40mg conversion rate at ~67%
- FDA approval of ProAir RespiClick
- Positive results for TEV-48125 in Phase IIb meeting primary and secondary endpoints for both chronic and episodic indications
- Reinforcement of CNS Leadership with Auspex Acquisition

**Revenues by Markets and Segments**

**Q1 - 2015**

**Revenues by Market**
- Europe 25%
- U.S. 59%
- ROW 16%

**Revenues by Segment**
- Generics 53%
- Specialty 39%
- Other* 8%

**Profit**** by Segment**

**Q1 - 2015**

- Generics 44%
- Specialty 54%
- Other* 3%

* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices.

**Teva Specialty pipeline - pending Auspex deal**

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>TV-46763 (abuse deterrent) Pain</td>
<td>Laquinimod Multiple sclerosis (progressive forms)</td>
<td>Fluticasone Propionate MDI Asthma</td>
<td>CEP-33237 ER Hydrocodone (abuse det.) US - Pain</td>
</tr>
<tr>
<td>TV-46139 (abuse deterrent) Pain</td>
<td>Laquinimod Huntington's disease</td>
<td>Fluticasone Salmeterol MDI Asthma</td>
<td>Copaxone® 40mg 3w ROW Multiple sclerosis</td>
</tr>
<tr>
<td>Fluticasone Salmeterol Spiromax EU Asthma, COPD</td>
<td>Pridopidine Huntington's disease</td>
<td>Fluticasone Salmeterol MDI Asthma</td>
<td>Copaxone® 20mg per Day Japan Multiple sclerosis</td>
</tr>
<tr>
<td>Reslizumab SC Asthma</td>
<td>TV-45070 Topical Osteoarthritis pain</td>
<td>QVAR® (BAI) US Asthma</td>
<td>Reslizumab IV Asthma</td>
</tr>
<tr>
<td>Fluticasone Salmeterol (MDI) EU Asthma, COPD</td>
<td>TV-45070 Topical Neuropathic pain</td>
<td>CEP-41750 (mesenchymal precursor cell) Chronic heart failure</td>
<td>Bendamustine Rapid Infusion* CLL, NHL</td>
</tr>
<tr>
<td>TEV-46017 (tidal inhaler) COPD</td>
<td>TEV-48125 (anti CGRP) Chronic and episodic migraine</td>
<td>SD-809 Tardive dyskinesia</td>
<td></td>
</tr>
<tr>
<td>TEV-48108 (tidal inhaler) COPD</td>
<td>CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction</td>
<td>SD-809 HD (Mid-2015 NDA filing)</td>
<td></td>
</tr>
<tr>
<td>TEV-90110 HIV</td>
<td>Albutropin Growth hormone deficiency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEV-90112 HIV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SD-809 Tourette syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SD-560 Idiopathic pulmonary fibrosis/other fibrotic conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Pipeline correct as of April 15, 2015. Phase 1 includes also projects designated for IND filing.